Other anti-CAIX antibodies selected later with a therapeutic focus showed much more promising preclinical results than G250 and cG250 when used in an unassociated manner, highlighting G119 and G37 with outstanding results for the treatment of ccRCC [24]. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.